Quick Answer
Travere Therapeutics, Inc. reported Operating Income of -$62.82 million for fiscal year 2025.
Travere Therapeutics, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$62.82M | +80.6% |
| 2024 | -$323.83M | +16.6% |
| 2023 | -$388.14M | -21.4% |
| 2022 | -$319.81M | -60.4% |
| 2021 | -$199.43M | -13.2% |
| 2020 | -$176.16M | -28.2% |
| 2019 | -$137.36M | -71.6% |
| 2018 | -$80.04M | -48.8% |
| 2017 | -$53.79M | +7.6% |
| 2016 | -$58.21M | -14.7% |
| 2015 | -$50.75M | +36.4% |
| 2014 | -$79.81M | -222.2% |
| 2013 | -$24.77M | +18.1% |
| 2012 | -$30.26M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $24.93M | +144.4% | +297.1% |
| June 30, 2025 | -$12.65M | +81.3% | +70.4% |
| March 31, 2025 | -$42.67M | +69.4% | +24.0% |
| September 30, 2024 | -$56.15M | +39.4% | +17.1% |
| June 30, 2024 | -$67.70M | +34.9% | +51.4% |
| March 31, 2024 | -$139.24M | -43.0% | -50.4% |
| September 30, 2023 | -$92.58M | -12.1% | +10.9% |
| June 30, 2023 | -$103.95M | -58.8% | -6.8% |
- Travere Therapeutics, Inc. showed an increase of +80.6% in Operating Income compared to the prior fiscal year.
- Over the 2012–2025 period, Travere Therapeutics, Inc.’s operating income has declined by 107.6% (from -$30.26 million to -$62.82 million).
- The most recent figure is from Travere Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 19, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: